Stay updated on Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.

Latest updates to the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page
- CheckyesterdayChange DetectedThe page now shows a consolidated Locations section for California, Michigan, and Missouri, replacing the separate California Locations, Michigan Locations, and Missouri Locations subsections; the revision is updated to v3.3.3 and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.4%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedTwo minor textual edits clarify PubMed-generated publications and update the page revision from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check37 days agoChange DetectedThe government funding/operating-status notice for the NIH Clinical Center was removed from the page, a minor housekeeping change that does not affect study details or user-facing functionality.SummaryDifference0.3%

- Check51 days agoChange DetectedObserved a minor administrative update (new last update date) with no substantive changes to study design, primary/secondary outcomes, eligibility criteria, or participating locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check80 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference2%

- Check87 days agoChange DetectedPage updates version from v3.0.2 to v3.1.0 and removes a specific disease resource; otherwise, core content remains unchanged.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.